1887

Abstract

Sulfonated phthalocyanines (Pcs) are cyclic tetrapyrroles that constitute a group of photosensitizers. In the presence of visible light and diatomic oxygen, Pcs produce singlet oxygen and other reactive oxygen species that have known degradation effects on lipids, proteins and/or nucleic acids. Pcs have been used successfully in the treatment of bacterial, yeast and fungal infections, but their use in the photodynamic inactivation of prions has never been reported. Here, we evaluated the photodynamic activity of the disodium salt of disulfonated hydroxyaluminium phthalocyanine (PcDS) against mouse-adapted scrapie RML prions . PcDS treatment of RML brain homogenate resulted in a time- and dose-dependent inactivation of prions. The photodynamic potential of Pcs offers a new way to inactivate prions using biodegradable compounds at room temperature and normal pressure, which could be useful for treating thermolabile materials and liquids.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.044727-0
2012-11-01
2020-01-24
Loading full text...

Full text loading...

/deliver/fulltext/jgv/93/11/2512.html?itemId=/content/journal/jgv/10.1099/vir.0.044727-0&mimeType=html&fmt=ahah

References

  1. Abdel-Haq H., Lu M., Cardone F., Liu Q. G., Puopolo M., Pocchiari M.. ( 2009;). Efficacy of phthalocyanine tetrasulfonate against mouse-adapted human prion strains. . Arch Virol 154:, 1005–1007. [CrossRef][PubMed]
    [Google Scholar]
  2. Baron E. D., Malbasa C. L., Santo-Domingo D., Fu P., Miller J. D., Hanneman K. K., Hsia A. H., Oleinick N. L., Colussi V. C., Cooper K. D.. ( 2010;). Silicon phthalocyanine (pc 4) photodynamic therapy is a safe modality for cutaneous neoplasms: results of a phase 1 clinical trial. . Lasers Surg Med 42:, 728–735. [CrossRef][PubMed]
    [Google Scholar]
  3. Bosque P. J., Prusiner S. B.. ( 2000;). Cultured cell sublines highly susceptible to prion infection. . J Virol 74:, 4377–4386. [CrossRef][PubMed]
    [Google Scholar]
  4. Calzavara-Pinton P. G., Venturini M., Sala R.. ( 2005;). A comprehensive overview of photodynamic therapy in the treatment of superficial fungal infections of the skin. . J Photochem Photobiol B 78:, 1–6. [CrossRef][PubMed]
    [Google Scholar]
  5. Cashman N. R., Caughey B.. ( 2004;). Prion diseases – close to effective therapy?. Nat Rev Drug Discov 3:, 874–884. [CrossRef][PubMed]
    [Google Scholar]
  6. Caughey W. S., Raymond L. D., Horiuchi M., Caughey B.. ( 1998;). Inhibition of protease-resistant prion protein formation by porphyrins and phthalocyanines. . Proc Natl Acad Sci U S A 95:, 12117–12122. [CrossRef][PubMed]
    [Google Scholar]
  7. Caughey B., Caughey W. S., Kocisko D. A., Lee K. S., Silveira J. R., Morrey J. D.. ( 2006;). Prions and transmissible spongiform encephalopathy (TSE) chemotherapeutics: a common mechanism for anti-TSE compounds?. Acc Chem Res 39:, 646–653. [CrossRef][PubMed]
    [Google Scholar]
  8. Caughey W. S., Priola S. A., Kocisko D. A., Raymond L. D., Ward A., Caughey B.. ( 2007;). Cyclic tetrapyrrole sulfonation, metals, and oligomerization in antiprion activity. . Antimicrob Agents Chemother 51:, 3887–3894. [CrossRef][PubMed]
    [Google Scholar]
  9. Charvériat M., Reboul M., Wang Q., Picoli C., Lenuzza N., Montagnac A., Nhiri N., Jacquet E., Guéritte F.. & other authors ( 2009;). New inhibitors of prion replication that target the amyloid precursor. . J Gen Virol 90:, 1294–1301. [CrossRef][PubMed]
    [Google Scholar]
  10. Choi Y. P., Gröner A., Ironside J. W., Head M. W.. ( 2011;). Comparison of the level, distribution and form of disease-associated prion protein in variant and sporadic Creutzfeldt–Jakob diseased brain using conformation-dependent immunoassay and Western blot. . J Gen Virol 92:, 727–732. [CrossRef][PubMed]
    [Google Scholar]
  11. Claessens C. G., Hahn U., Torres T.. ( 2008;). Phthalocyanines: from outstanding electronic properties to emerging applications. . Chem Rec 8:, 75–97. [CrossRef][PubMed]
    [Google Scholar]
  12. Collinge J., Gorham M., Hudson F., Kennedy A., Keogh G., Pal S., Rossor M., Rudge P., Siddique D.. & other authors ( 2009;). Safety and efficacy of quinacrine in human prion disease (PRION-1 study): a patient-preference trial. . Lancet Neurol 8:, 334–344. [CrossRef][PubMed]
    [Google Scholar]
  13. Howlett D., Cutler P., Heales S., Camilleri P.. ( 1997;). Hemin and related porphyrins inhibit β-amyloid aggregation. . FEBS Lett 417:, 249–251. [CrossRef][PubMed]
    [Google Scholar]
  14. Jancula D., Drábková M., Cerný J., Karásková M., Korínková R., Rakusan J., Marsálek B.. ( 2008;). Algicidal activity of phthalocyanines – screening of 31 compounds. . Environ Toxicol 23:, 218–223. [CrossRef][PubMed]
    [Google Scholar]
  15. Jancula D., Marsálek B., Novotná Z., Cerný J., Karásková M., Rakusan J.. ( 2009;). In search of the main properties of phthalocyanines participating in toxicity against cyanobacteria. . Chemosphere 77:, 1520–1525. [CrossRef][PubMed]
    [Google Scholar]
  16. Jori G., Brown S. B.. ( 2004;). Photosensitized inactivation of microorganisms. . Photochem Photobiol Sci 3:, 403–405. [CrossRef][PubMed]
    [Google Scholar]
  17. Julak J., Janouskova O., Scholtz V., Holada K.. ( 2011;). Inactivation of prions using electrical DC discharges at atmospheric pressure and ambient temperature. . Plasma Process Polym 8:, 316–323. [CrossRef]
    [Google Scholar]
  18. Kocisko D. A., Baron G. S., Rubenstein R., Chen J. C., Kuizon S., Caughey B.. ( 2003;). New inhibitors of scrapie-associated prion protein formation in a library of 2000 drugs and natural products. . J Virol 77:, 10288–10294. [CrossRef][PubMed]
    [Google Scholar]
  19. Kocisko D. A., Engel A. L., Harbuck K., Arnold K. M., Olsen E. A., Raymond L. D., Vilette D., Caughey B.. ( 2005;). Comparison of protease-resistant prion protein inhibitors in cell cultures infected with two strains of mouse and sheep scrapie. . Neurosci Lett 388:, 106–111. [CrossRef][PubMed]
    [Google Scholar]
  20. Lee E. N., Cho H. J., Lee C. H., Lee D., Chung K. C., Paik S. R.. ( 2004;). Phthalocyanine tetrasulfonates affect the amyloid formation and cytotoxicity of alpha-synuclein. . Biochemistry 43:, 3704–3715. [CrossRef][PubMed]
    [Google Scholar]
  21. Mahal S. P., Baker C. A., Demczyk C. A., Smith E. W., Julius C., Weissmann C.. ( 2007;). Prion strain discrimination in cell culture: the cell panel assay. . Proc Natl Acad Sci U S A 104:, 20908–20913. [CrossRef][PubMed]
    [Google Scholar]
  22. Ogunsipe A., Nyokong T.. ( 2005;). Photophysical and photochemical studies of sulphonated non-transition metal phthalocyanines in aqueous and non-aqueous media. . J Photochem Photobiol Chem 173:, 211–220. [CrossRef]
    [Google Scholar]
  23. Panigaj M., Brouckova A., Glierova H., Dvorakova E., Simak J., Vostal J. G., Holada K.. ( 2011;). Underestimation of the expression of cellular prion protein on human red blood cells. . Transfusion 51:, 1012–1021. [CrossRef][PubMed]
    [Google Scholar]
  24. Paspaltsis I., Kotta K., Lagoudaki R., Grigoriadis N., Poulios I., Sklaviadis T.. ( 2006;). Titanium dioxide photocatalytic inactivation of prions. . J Gen Virol 87:, 3125–3130. [CrossRef][PubMed]
    [Google Scholar]
  25. Paspaltsis I., Berberidou C., Poulios I., Sklaviadis T.. ( 2009;). Photocatalytic degradation of prions using the photo-Fenton reagent. . J Hosp Infect 71:, 149–156. [CrossRef][PubMed]
    [Google Scholar]
  26. Pasternack R. F., Gibbs E. J., Sibley S., Woodard L., Hutchinson P., Genereux J., Kristian K.. ( 2006;). Formation kinetics of insulin-based amyloid gels and the effect of added metalloporphyrins. . Biophys J 90:, 1033–1042. [CrossRef][PubMed]
    [Google Scholar]
  27. Priola S. A., Raines A., Caughey W. S.. ( 2000;). Porphyrin and phthalocyanine antiscrapie compounds. . Science 287:, 1503–1506. [CrossRef][PubMed]
    [Google Scholar]
  28. Priola S. A., Raines A., Caughey W.. ( 2003;). Prophylactic and therapeutic effects of phthalocyanine tetrasulfonate in scrapie-infected mice. . J Infect Dis 188:, 699–705. [CrossRef][PubMed]
    [Google Scholar]
  29. Prusiner S. B.. ( 1998;). Prions. . Proc Natl Acad Sci U S A 95:, 13363–13383. [CrossRef][PubMed]
    [Google Scholar]
  30. Qi Y., Wang J. K., McMillian M., Chikaraishi D. M.. ( 1997;). Characterization of a CNS cell line, CAD, in which morphological differentiation is initiated by serum deprivation. . J Neurosci 17:, 1217–1225.[PubMed]
    [Google Scholar]
  31. Rakusan J., Karaskova M., Holada K., Janouskova O.. ( 2011;). Way of inactivation of pathogenic prions using reactive oxygen species generated by interaction of suitable photosensitizers with light and oxygen. 6 January 2011. Czech Patent 303355.
  32. Sheng C., Pogue B. W., Wang E., Hutchins J. E., Hoopes P. J.. ( 2004;). Assessment of photosensitizer dosimetry and tissue damage assay for photodynamic therapy in advanced-stage tumors. . Photochem Photobiol 79:, 520–525. [CrossRef][PubMed]
    [Google Scholar]
  33. Sigler K., Chaloupka J., Brozmanová J., Stadler N., Höfer M.. ( 1999;). Oxidative stress in microorganisms – I. Microbial vs. higher cells – damage and defenses in relation to cell aging and death. . Folia Microbiol (Praha) 44:, 587–624. [CrossRef][PubMed]
    [Google Scholar]
  34. Stewart L. A., Rydzewska L. H. M., Keogh G. F., Knight R. S. G.. ( 2008;). Systematic review of therapeutic interventions in human prion disease. . Neurology 70:, 1272–1281. [CrossRef][PubMed]
    [Google Scholar]
  35. Taylor D. M.. ( 2000;). Inactivation of transmissible degenerative encephalopathy agents: a review. . Vet J 159:, 10–17. [CrossRef][PubMed]
    [Google Scholar]
  36. Todd N. V., Morrow J., Doh-ura K., Dealler S., O’Hare S., Farling P., Duddy M., Rainov N. G.. ( 2005;). Cerebroventricular infusion of pentosan polysulphate in human variant Creutzfeldt–Jakob disease. . J Infect 50:, 394–396. [CrossRef][PubMed]
    [Google Scholar]
  37. Trevitt C. R., Collinge J.. ( 2006;). A systematic review of prion therapeutics in experimental models. . Brain 129:, 2241–2265. [CrossRef][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.044727-0
Loading
/content/journal/jgv/10.1099/vir.0.044727-0
Loading

Data & Media loading...

Supplements

Supplementary material 

PDF

Most cited articles

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error